<DOC>
	<DOCNO>NCT02731573</DOCNO>
	<brief_summary>This study aim assess anti-infective efficacy D-PLEX period 3 month post operation well safety period 6 month , prevent sternal infection post cardiac surgery patient age 18 , include high risk patient infection . This study 2 part study : part 1 single arm , part 2 randomize control study .</brief_summary>
	<brief_title>Safety Efficacy D-PLEX Prevention Sternal Infection Post Cardiac Surgery</brief_title>
	<detailed_description>D-PLEX new formulation extend control release Doxycycline , impregnate synthetic , β Tri-Calcium Phosphate ( β-TCP ) . The component extend controlled release antibiotic formulation doxycycline hyclate , poly ( DL-lactide-co-glycolide ) PLGA , lipid matrix comprise cholesterol , 2 phosphatidyl-choline phospholipid , specifically dipalmitoylphosphatidylcholine ( DPPC ) distearoyl phosphatidylcholine ( DSPC ) . Subjects meet eligibility criterion provide sign informed consent , enrol study treat D-PLEX concomitantly standard care . D-PLEX administer single application cardiac surgery ( index procedure ) immediately prior sternal closure , adjunct standard care . The study ass efficacy safety control release antibiotic ( doxycycline ) reduction number sternal infection observe treatment period subject age 18 year , include patient high risk infection . Additional follow prolong safety assessment , do follow 24 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Surgical Wound Infection</mesh_term>
	<criteria>1 . Male nonpregnant female 18 year old 2 . Female childbearing potential negative serum pregnancy test prior index procedure . Note : All female childbearing potential must agree use highly effective method contraception ( double barrier , oral parenteral hormonal , intrauterine device spermicide ) consistently correctly duration study . 3 . Subjects undergo elective urgent cardiac surgery , preoperative stable hemodynamically . 4 . Subjects ( 20≤BMI≤40 ) 5 . Subjects sign write informed consent . 1 . Received investigational drug within 30 day start study within 5½ halflives ( pharmacokinetic pharmacodynamics ) prior enrollment ( whichever longer ) . 2 . Are ineligible receive treatment : Any preoperative active significant infection Antibiotic sensitivity Doxycycline and/or tetracycline family drug Known allergy 3 substance . ( Patients fill allergy questioner enrolment process ) History allergic/hypersensitivity reaction substance require hospitalization and/or treatment intravenous steroids/epinephrine opinion investigator patient high risk develop severe allergic / hypersensitivity reaction . History uncontrolled Asthma ( GINA IIIIV ) History chronic urticaria 3 . Pregnant breastfeed woman . 4 . Subjects take oral IV doxycycline last 4 week prior screen . 5 . Subjects undergo cardiac/open chest surgery , classify emergency . 6 . Immunocompromised subject reason , screen . 7 . Subjects undergone TIA/ CVA within last 3 month prior enrollment . 8 . Subjects previously underwent cardiac surgery midsternum . 9 . In opinion investigator , subject eligible participate study due cognitive status , medical condition medication status ( item list )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Mediastenitis</keyword>
</DOC>